


AstraZeneca Pharma India Limited
Regd. Office 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Financial results for the quarter and year ended 31 March 2012

Part I		Rs in lakhs (except for number of shares)				
Sl	Particulars	3 months ended 31/03/2012	3 months ended 31/03/2011	3 months ended 31/12/2011	Year to date figure for 12 months ended 31/03/2012	Previous accounting year (15 months period) ended 31/03/2011
		(Unaudited) ¹	(Unaudited) ¹	(Unaudited) ¹	(Audited)	(Audited)
1	Income from operations					
	a) Net sales/ income from operations (net of excise duty)	9,168.98	12,667.68	15,348.33	53,127.97	59,402.50
	b) Other operating income	9.70	5.75	3.89	24.05	28.23
	Total income from operations (net)	9,178.68	12,673.43	15,352.22	53,152.02	59,430.73
2	Expenditure					
	(a) Cost of materials consumed	1,409.45	1,640.44	1,349.33	7,151.68	7,604.40
	(b) Purchase of stock-in-trade	834.28	2,418.88	5,320.28	11,923.13	11,681.17
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,216.16	(99.78)	(1,941.87)	(1,210.38)	(1,258.95)
	(d) Employee benefits expense	5,791.09	3,829.61	3,523.09	16,191.24	15,049.76
	(e) Depreciation and amortisation expense	181.03	173.63	188.81	733.66	881.28
	(f) Other expenses	3,843.76	3,218.77	4,859.03	16,070.05	16,078.36
	Total expenses	14,275.77	11,183.55	13,298.67	50,859.58	49,936.02
3	Profit/(loss) from operations before other income, finance costs and exceptional items (1-2)	(5,097.09)	1,489.88	2,053.55	2,292.44	9,494.71
4	Other income	301.41	214.04	146.43	633.04	599.91
5	Profit/(loss) from ordinary activities before finance costs and exceptional items (3+4)	(4,895.68)	1,703.92	2,199.98	2,925.48	10,094.62
6	Finance costs	-	-	-	-	-
7	Profit/(loss) from ordinary activities after finance costs but before exceptional items (5-6)	(4,895.68)	1,703.92	2,199.98	2,925.48	10,094.62
8	Exceptional items					
9	Profit/(loss) from ordinary activities before tax (7+8)	(4,895.68)	1,703.92	2,199.98	2,925.48	10,094.62
10	Tax expense/(refund), including deferred tax charge/(credit)	(1,395.23)	868.53	706.24	948.97	3,681.66
11	Net profit/(loss) from ordinary activities after tax (9-10)	(3,500.45)	835.39	1,493.74	1,976.51	6,412.96
12	Extraordinary item					
13	Net profit/(loss) for the period (11-12)	(3,500.45)	835.39	1,493.74	1,976.51	6,412.96
14	Paid-up equity share capital (Paid value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves including revaluation reserves as per the balance sheet of previous accounting year				18,428.52	17,468.96
16	Basic and diluted earnings (Rs) per share (not annualised)	(13.20)	3.34	5.97	7.91	25.65
Part II						
A. Particulars of shareholding						
1	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
2	Promoters and promoter group shareholding					
	a) Pledged/Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%
B. Particulars						
		3 months ended 31/03/2012				
	Investor complaints					
	Pending at the beginning of the quarter		Nil			
	Received during the quarter		1			
	Disposed of during the quarter		1			
	Remaining unresolved at the end of the quarter		Nil			




Notes:

- 1 Figures for the 3 months ended 31 March 2012 and 31 March 2011 are the balancing figures between audited figures in respect of full financial year period and the published year to date figures upto the previous quarter of the respective financial year period. Also, the figures upto the period ended 31 December 2011 and 31 December 2010 were only reviewed and not subjected to audit. The statutory auditors have issued an unqualified audit report. The audit report has been filed with the stock exchange and is also available on the Company's website.
- 2 The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 11 May 2012.
- 3 The Board of Directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". The financial accounts and annual report for the year ending 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current year ended 31 March 2012 are for a 12 months period, while the corresponding figures are for a 15 months period and hence not strictly comparable.
- 4 The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- 5 Employee benefit expense for the quarter and year ended 31 March 2012 include provision for terminal compensation benefits payable under the voluntary retirement scheme rolled out by the Company amounting to Rs 1,877.18 lakhs (Quarter ended 31 March 2011: Rs Nil, Period ended 31 March 2011: Rs 146.60 lakhs).
- 6 The sales for the quarter and year ended 31 March 2012 is impacted by following items:
 (a) As a measure of extra and abundant caution, the Company undertook a voluntary recall of sterile products manufactured at its plant amounting to Rs 268.26 lakhs, following AstraZeneca's Global quality audit. As a precautionary measure, the Company also voluntarily suspended production temporarily to review manufacturing practices at the plant resulting in a temporary interruption of supplies. The net sales of the products affected by supply constraint amounted to Rs 7,720.13 lakhs in the quarter ended 31 March 2012 as against Rs 6,068.33 lakhs in the quarter ended 31 December 2011. The Company has recommenced the production in phased manner.
 (b) Provision for potential prior period charge back amounting to Rs 1,430.60 lakhs (Quarter ended 31 March 2011: Rs Nil, Period ended 31 March 2011: Rs Nil) from customers.
- 7 A foreign national was appointed as Whole time Director of the Company during the year. The Company has filed an application with the Central Government under the Companies Act, 1956 seeking approval for the appointment of, and remuneration payable to, the said director. The application is pending before the Central Government.
- 8 A First Information Report (FIR) was filed by the Central Bureau of Investigation against the Company on 23 February 2012 wherein it is alleged that the Company submitted a false affidavit with respect to rates quoted by the Company to the institution (Directorate of Health Services, Delhi) and unknown officials of the Company and other private persons conspired to evade the recovery proceedings by DHS. The Company is fully cooperating with the ongoing investigations.
- 9 The Board of Directors at their meeting held on 11 May 2012 have recommended Rs 3.50 (Previous period Rs 10) as dividend per equity share of Rs 2 each for the year ended 31 March 2012.

Bangalore

Dated: 11 May 2012

By Order of the Board of Directors
 For AstraZeneca Pharma India Limited

 Anandh Balasundaram
 Managing Director




AstraZeneca Pharma India Limited
Regd Office : "Avishkar" Off Bellary Road , Hebbal Bangalore - 560 024
Statement of assets and liabilities

(Rs in lakhs)

Sl.no.	Particulars	As at 31 March 2012 (Audited)	As at 31 March 2011 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	500.00	500.00
	(b) Reserves and Surplus	18,428.52	17,468.96
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	18,928.52	17,968.96
2	Share application money pending allotment	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	54.44	52.44
	(d) Long-term provisions	-	309.92
	Sub-total - Non-current liabilities	54.44	362.36
4	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	1,776.54	1,437.58
	(c) Other current liabilities	8,619.33	6,270.78
	(d) Short-term provisions	4,829.60	4,828.52
	Sub-total - Current liabilities	15,225.47	12,536.88
	TOTAL - EQUITY AND LIABILITIES	34,208.43	30,868.20
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	9,018.24	5,138.77
	(b) Non-current investments	0.57	0.57
	(c) Deferred tax assets (net)	1,776.23	754.19
	(d) Long-term loans and advances	3,460.40	2,690.67
	(e) Other non-current assets	196.92	328.98
	Sub-total - Non-current assets	14,452.36	8,913.18
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	7,509.69	5,720.26
	(c) Trade receivables	3,230.79	4,371.42
	(d) Cash and bank balances	5,365.07	8,539.02
	(e) Short-term loans and advances	2,415.95	2,832.71
	(f) Other current assets	1,234.57	491.61
	Sub-total - Current assets	19,756.07	21,955.02
	TOTAL - ASSETS	34,208.43	30,868.20

Note:

The Board of Directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". The financial accounts and annual report for the year ending 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current year ended 31 March 2012 are for a 12 months period, while the corresponding figures are for a 15 months period and hence not strictly comparable.




AstraZeneca Pharma India Limited
Regd. Office : Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

Sl.no.	Particulars	(Rs in lakhs)			
		3 months ended 31/03/2012 (Unaudited)¹	3 months ended 31/03/2011 (Unaudited)¹	3 months ended 31/12/2011 (Unaudited)¹	Year to date figure for 12 months ended 31/03/2012 (Audited)
1	Segment revenue				Previous accounting year (15 months period) ended 31/03/2011 (Audited)
	(a) Healthcare	8,303.82	12,336.22	14,520.44	57,464.43
	(b) Others	874.86	337.21	831.78	1,966.30
	Total	9,178.68	12,673.43	15,352.22	59,430.73
	Less: Inter-segment revenue				
	Net income from operations	9,178.68	12,673.43	15,352.22	59,430.73
2	Segment results				
	Profit/(loss) before tax and interest				
	(a) Healthcare	(5,122.57)	1,539.44	2,047.28	9,382.63
	(b) Others	25.48	(49.56)	6.27	112.08
Total	(5,097.09)	1,489.88	2,053.55	9,494.71	
	Add: Other income	201.41	214.04	146.43	599.91
	Less: Interest				
	Total profit/(loss) before tax	(4,895.68)	1,703.92	2,199.98	10,094.62
3	Capital employed				
	(a) Healthcare	11,722.25	12,122.33	15,527.13	12,122.33
	(b) Others	817.67	644.20	562.23	644.20
	(c) Unallocated	6,388.60	5,202.43	7,156.55	5,202.43
Total	18,928.52	17,968.96	23,245.91	18,928.52	17,968.96

Notes:

- Figures for the 3 months ended 31 March 2012 and 31 March 2011 are the balancing figures between audited figures in respect of full financial year/period and the published year to date figures upto the previous quarter of the respective financial year/period. Also, the figures upto the period ended 31 December 2011 and 31 December 2010 were only reviewed and not subjected to audit.
- Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- The Board of Directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". The financial accounts and annual report for the year ending 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current year ended 31 March 2012 are for a 12 months period, while the corresponding figures are for a 15 months period and hence not strictly comparable.



[Handwritten signature]

B S R & Co.

(Registered)

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1, Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 3980 6000
Fax +91 80 3980 6999


To Board of Directors of AstraZeneca Pharma India Limited

We have audited the accompanying annual financial results of AstraZeneca Pharma India Limited ("the Company") for the year ended 31 March 2012, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. Attention is drawn to the fact that the figures for the quarter ended 31 March 2012 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter were reviewed and were not subjected to an audit.

These financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results upto the end of the third quarter which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of the annual financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India and in compliance with Clause 41 of the Listing Agreement.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Without qualifying our opinion, we draw attention to note 7 in the financial results for the quarter and year ended 31 March 2012 wherein it is stated that a foreign national, was appointed as whole time director during the year. The appointment and remuneration payable for the year is subject to the approval of the Central Government. The Company has filed an application with the central government for said appointment and remuneration payable.



BSR & Co.

In our opinion and to the best of our information and according to the explanations given to us these financial results:


- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the year ended 31 March 2012.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

for BSR & Co.

Chartered Accountants

Firm Registration Number: 101248W



Zubin Shelkary

Partner

Membership No: 048814

Place: Bangalore

Date: 11 May 2012